多替阿巴拉米片需要长期服用吗？

(Chemical name: doptabalamid tablets), launched in mainland China in January 2018. This product consists of two nucleoside reverse transcriptase inhibitors (abacavir and abalamib) and an integrase inhibitor (dolutegravir). It is a three-in-one compound drug, one tablet taken once a day.

Usage and dosage of Dotiabalamid Tablets (Suimeikai): This product should be taken under the guidance of a physician with experience in HIV infection. Dosage Adults and Adolescents (Weighing at least 40 kg) For adults and adolescents, the recommended dose is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product because this product is a fixed-dose tablet and the dose cannot be reduced. This product is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. Missed dose If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. Patients with renal impairment and creatinine clearance less than 50 mL/min are not recommended to take this product (see [Pharmacokinetics]). Hepatic Impairment Abacavir is primarily metabolized by the liver.

All drugs have certain toxic effects. Therefore, Suimeikai also recommends that it is not suitable for long-term use. Generally speaking, if there is still no effect after taking this product for a week, you should stop using it. If the effect is good, you should use it under the guidance of a doctor to achieve the purpose of medication safety.